Cytokinetics (CYTK) Q2 2024 earnings summary

Executive summary

• Significant progress in late-stage clinical programs, especially aficamten, with strong SEQUOIA-HCM results presented at ESC Heart Failure 2024, supporting its potential as a next-in-class cardiac myosin inhibitor for HCM patients.

• Productive regulatory interactions with FDA, EMA, and Chinese authorities, with rolling NDA submission for aficamten initiated in July and MAA submission to EMA planned for Q4 2024.

• Strengthened balance sheet through a $563.2M public offering and $575M strategic financing with Royalty Pharma, ending Q2 with $1.4B in cash and investments.

• Advanced commercial readiness for aficamten, including market development campaigns, payer engagement, and sales team planning.

• Expanded late-stage pipeline with ongoing trials for omecamtiv mecarbil and CK-586.

Financial highlights

• Q2 2024 revenues were $0.2M, down from $0.9M in Q2 2023, primarily from Ji Xing collaboration agreements.

• R&D expenses were $79.6M (down from $83.2M YoY), while G&A expenses rose to $50.8M (from $39.7M YoY), reflecting increased commercial readiness investments.

• Net loss was $143.3M ($1.31/share), compared to $128.6M ($1.34/share) in Q2 2023.

• Cash, cash equivalents, and investments totaled $1.4B at Q2 end, up from $634.3M at March 31, 2024.

• Operating expenses for Q2 2024 were $130.4M, up from $122.9M in Q2 2023.

Outlook and guidance

• NDA for aficamten to be completed in Q3 2024; MAA to EMA in Q4 2024; China NDA planned for H2 2024.

• MAPLE-HCM enrollment to complete in Q3 2024, with results expected H1 2025.

• ACACIA-HCM and CEDAR-HCM enrollment ongoing, with ACACIA completion targeted for 2025.

• Confirmatory Phase III trial for omecamtiv mecarbil and Phase IIA for CK-586 to start in Q4 2024.

• Updated 2024 GAAP operating expense guidance: $555M–$575M; non-GAAP: $445M–$470M; net cash utilization: $400M–$420M.